Paper Details

  1. Home
  2. Paper Details

Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD stage II treatment of the autoimmune diseases.

Author: ChenShun-Le, DarmawanJohn, DavatchiFereydoun, HaqSyed Atiqul, NasutionA Remy, ZengQingyu, ZhaoDongbao

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study investigates the efficacy of a 'step-down bridge combination' of 5 immunosuppressants in achieving induction and maintenance of remission in ankylosing spondylitis (AS) refractory to nonsteroidal antiinflammatory drugs.
Paper Details　
Original Abstract of the Article :
To achieve induction and maintenance of remission in ankylosing spondylitis (AS) refractory to nonsteroidal antiinflammatory drugs with "step-down bridge combination" of 5 immunosuppressants, as an alternative to costly biologic DMARD. Primary endpoints were the percentage of patients achieving ASAS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/17143982

データ提供：米国国立医学図書館（NLM）

Ankylosing Spondylitis: A Multi-faceted Approach

Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects the spine and other joints. This study investigates a novel treatment strategy for AS that is refractory to conventional medications. It utilizes a multi-pronged approach, combining five immunosuppressants in a step-down bridge combination to achieve remission. This is a game-changer for individuals with AS who are resistant to traditional therapies.

A Multi-faceted Approach to AS

The study showcases the potential of this innovative combination therapy in achieving long-term remission of AS. The promising results are highlighted by the significant percentage of patients achieving ASAS 20, 50, and 70 responses after six years of treatment.

A Ray of Hope for AS Patients

This research offers hope for individuals suffering from AS who have not responded to conventional treatments. It showcases the potential of personalized and multifaceted therapies in achieving remission. This research reminds us that even in the vastness of the medical desert, there are innovative solutions waiting to be discovered.

Dr.Camel's Conclusion

This research is like a refreshing spring in the desert of AS treatment. It highlights the potential of combining multiple therapies to achieve long-term remission in patients who have not responded to conventional medications.

Date :
  1. Date Completed 2007-03-01
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

17143982

DOI: Digital Object Identifier

0315162X-33-2484

Related Literature

Article Analysis
・Side Effects of mycophenolate injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.